Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,021,079
  • Shares Outstanding, K 569,318
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,400 K
  • 60-Month Beta -1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/02/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.8600 +24.13%
on 08/19/20
5.1500 -31.07%
on 09/08/20
+0.4800 (+15.64%)
since 08/18/20
3-Month
2.7600 +28.62%
on 08/18/20
10.0100 -64.54%
on 06/30/20
+0.3500 (+10.94%)
since 06/18/20
52-Week
0.2610 +1,260.15%
on 12/03/19
10.0100 -64.54%
on 06/30/20
+3.1600 (+810.26%)
since 09/18/19

Most Recent Stories

More News
CytoDyn's CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

CYDY : 3.5500 (+3.80%)
Innovative Diagnostic Techniques are in Demand as Social Distancing Rules Ease

, /PRNewswire/ -- The pandemic has drastically changed the world's social and economic landscape, and it's unclear what the next steps are in combating the spread of the viral infection. Now, that social...

SBFM : 0.0225 (-3.02%)
TPTW : 0.0566 (-1.57%)
CYDY : 3.5500 (+3.80%)
ONTX : 0.3218 (+28.72%)
VYST : 0.0303 (-1.94%)
CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

CYDY : 3.5500 (+3.80%)
U.K. MHRA Grants Meeting to CytoDyn to Discuss Fast Track Approval of Leronlimab for COVID-19 Patients

U.S. FDA schedules Type A meeting with CytoDyn to discuss BLA filing for HIV

CYDY : 3.5500 (+3.80%)
Global Health Leaders Join CytoDyn's Scientific Advisory Board

Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab

CYDY : 3.5500 (+3.80%)
CytoDyn to Hold Conference Call on September 2 to Provide Update on Timelines for Multiple Regulatory and Clinical Initiatives Including COVID-19 Potential Approvals

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

CYDY : 3.5500 (+3.80%)
Global Pandemic: This is When the World May be Able to Return to Normal

Months into the global pandemic, the world is up to 23.9 million cases, with 820,286 unfortunate deaths. ...

RVVTF : 0.1945 (-2.75%)
CYDY : 3.5500 (+3.80%)
PFE : 36.63 (-0.52%)
NVAX : 108.36 (-6.19%)
BNTX : 67.00 (+0.33%)
RVV.CN : 0.255 (-3.77%)
CytoDyn Reaches Enrollment of 195 Patients in its Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

Interim analysis to commence after 28 days; results anticipated by mid-October

CYDY : 3.5500 (+3.80%)
After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.'s MHRA Accepts CytoDyn's Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

Patient enrollment to commence immediately

CYDY : 3.5500 (+3.80%)
To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

CYDY : 3.5500 (+3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CYDY with:

Key Turning Points

2nd Resistance Point 3.6833
1st Resistance Point 3.6167
Last Price 3.5500
1st Support Level 3.4267
2nd Support Level 3.3033

See More

52-Week High 10.0100
Fibonacci 61.8% 6.2859
Fibonacci 50% 5.1355
Fibonacci 38.2% 3.9851
Last Price 3.5500
52-Week Low 0.2610

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar